Semaglutide and Limb Events: What We Know

Two cardiologists used a September 17, 2026 editorial in the European Journal of Preventive Cardiology to ask a pointed question about semaglutide: does its cardiovascular benefit reach all the way down to the legs? Maria Elena Canonico and Marc Bonaca titled the piece "Semaglutide and Limb Events: Expanding the Cardiovascular Prevention Paradigm?"^[1] The question mark in that title is doing real work. The evidence behind it is genuinely encouraging. It is also earlier and narrower than headlines about it are likely to make it sound.

Why cardiologists are asking this question

Semaglutide's cardiovascular story already runs well beyond blood sugar. The SELECT trial found a reduced risk of cardiovascular death, heart attack, and stroke in adults with obesity and existing heart disease, and that benefit is now written into the Wegovy label as an approved indication for cardiovascular risk reduction^[4]. Peripheral artery disease (PAD, the narrowing of arteries that carry blood to the legs) shares the same underlying process as heart attack and stroke: atherosclerosis, the buildup of fatty plaque inside artery walls. If a drug slows that process in the coronary arteries, the logical next question is whether it also helps in the leg arteries. That is the question Canonico and Bonaca's editorial frames.

PAD itself is a badly underserved area of medicine. It carries a high risk of amputation and death, yet it has historically drawn far less drug-development attention than coronary disease. A therapy that already treats diabetes and obesity, and that patients with PAD frequently also have, would be a meaningful addition if the leg-specific benefit holds up under closer scrutiny.

What the limb-event meta-analysis found

The editorial leans on a meta-analysis published in the same journal seven months earlier. Andrea Cesaro and colleagues pooled 19 randomized controlled trials covering 51,557 participants and looked specifically at major limb events: amputations, revascularization procedures (surgery or stenting to restore blood flow), and disease progression^[3]. Semaglutide was associated with a meaningfully lower risk of those events compared with control treatment, odds ratio 0.70 (95% CI 0.60-0.82, p<0.0001). The benefit held up across diabetes and obesity subgroups, across the injectable and oral formulations, and regardless of whether patients were also taking an SGLT2 inhibitor^[3].

That is a large, consistent signal across a large pooled population. It is also a signal built mostly from secondary and safety-reporting data inside trials that were not designed around limb outcomes as their main question. Most of the 19 trials enrolled people for diabetes, obesity, or general cardiovascular risk, not specifically for peripheral artery disease. Limb events were something researchers counted along the way, not the reason the trials were run.

What STRIDE actually measured

The one trial designed specifically around PAD is STRIDE, led by Bonaca and published in the Lancet in 2025. It randomized 792 adults with type 2 diabetes and symptomatic PAD to weekly semaglutide or placebo for 52 weeks^[2]. The primary result: median maximum walking distance on a treadmill test rose to 1.21 times baseline on semaglutide versus 1.08 times baseline on placebo, an estimated treatment ratio of 1.13 (95% CI 1.06-1.21, p=0.0004)^[2]. Patients could walk further before leg pain stopped them.

That is a functional outcome, how far someone can walk, not a hard clinical endpoint like amputation or death. It matters to patients living with claudication (the cramping leg pain PAD causes during exercise), and it is the kind of result regulators and clinicians take seriously. But it is a different question from whether semaglutide actually prevents amputations, and STRIDE was not sized or designed to answer that question on its own.

What this does not show

No completed trial has enrolled a broad PAD population specifically to test amputation or major limb events as its primary endpoint. STRIDE measured walking function in people who also had type 2 diabetes; the Cesaro meta-analysis measured limb events as a pooled secondary signal across trials built for other purposes^[3]. Neither is the same as a dedicated, adequately powered outcomes trial with amputation as the primary question, and no such trial has reported.

The regulatory record reflects that gap. The current Wegovy prescribing information lists cardiovascular risk reduction, weight management, and metabolic dysfunction-associated steatohepatitis as approved indications. It does not include peripheral artery disease or limb events^[4]. Nothing about the STRIDE result or the meta-analysis has changed that. Prescribing for PAD-specific benefit is not something the current label supports, and the editorial itself frames the idea as a paradigm worth testing further, not a settled finding.

What this means for patients now

For someone with type 2 diabetes and diagnosed PAD already taking semaglutide for glucose control or weight, the STRIDE data is a genuine reason for optimism about walking capacity, on top of the established cardiovascular case. For someone considering starting semaglutide specifically because of a leg-artery diagnosis, the honest answer is that the evidence is promising but still building, and the drug is not approved or labeled for that specific purpose.

Other GLP-1 class peptides are earlier still on this question. Tirzepatide has its own cardiovascular development program underway, but nothing published yet speaks directly to limb outcomes the way STRIDE does for semaglutide. Anyone weighing this evidence for their own care, rather than reading about it out of general interest, should bring the STRIDE and meta-analysis results to a clinician who can weigh them against a full medical history rather than deciding from a headline.